Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade

Table 1 Characteristics of the patients

Patient No.	Age	Sex	Stage of esophageal cancer	Former treatment	Symptoms
1	68	M	T2, N1, M0: Stage IIB	Esophagectomy + chemotherapy	Dyspnea, tachycardia
2	69	M	T3, N1, M0: Stage III	Esophagectomy + chemotherapy	Dyspnea, tachycardia
3	64	M	T2, N1, M0: Stage III	Esophagectomy + chemotherapy	Dyspnea
4	70	M	T3, N1, M1a: Stage IVA	Esophagectomy + chemotherapy	Dyspnea, tachycardia
5	71	M	T2, N1, M1a: Stage IVA	Chemoradiotherapy	Dyspnea, tachycardia
6	65	M	T2, N1, M0: Stage IIB	Esophagectomy + chemotherapy	Dyspnea, tachycardia
7	62	M	T2, N1, M1a: Stage IVA	Chemoradiotherapy	Dyspnea

Table 2 Outcomes of intrapericardial instillation of cisplatin

Patient No.	Amount of fluid (mL)	CDDP instillation (mg) × times	Duration of drainage (d)	Side effect	Reaccumulation of fluid
1	580	10 × 2	5	-	-
2	400	10 × 2	5	-	-
3	760	10 × 3	8	-	-
4	980	10 × 3	8	Nausea	-
5	1200	10 × 5	13	Nausea	-
6	685	10 × 3	8	-	-
7	870	10 × 3	8	-	-

CDDP: Cisplatin.

Table 3 Outcomes of the patients

Patient No.	Additional therapy (systemic)	Survival (d)	Cause of death
1	5-Fu + CDDP	126	Lung and pleural metastases
2	5-Fu + CDDP	268	Pleural metastases
3	5-Fu + CDDP	137	Lung and bone metastases
4	-	68	Lung and pleural metastases
5	-	61	Lung and bone metastases
6	-	104	Lung and pleural metastases
7	-	77	Pleural metastases

5-Fu: 5-fluorouracil.